Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr. Márquez Rodas on the Preliminary Efficacy of BO-112/Pembrolizumab in Advanced Melanoma
November 23rd 2021Iván Márquez Rodas, MD, PhD, discusses the preliminary results of the phase 2 SPOTLIGHT203 trial, which is evaluating the efficacy and safety of BO-112 plus pembrolizumab in patients with advanced melanoma.
Dr. Wildiers on the Final Results of the AIPAC Trial in HR+/HER2- Metastatic Breast Cancer
November 19th 2021Hans Wildiers, MD, medical oncologist, Department of Medical Oncology, full professor, Faculty of Medicine, member, Laboratory of Experimental Oncology, University Hospital Leuven, Leuven, Belgium, discusses the final results of the phase 2b AIPAC trial (NCT02614833) in hormone receptor (HR)–positive, HER2-negative metastatic breast cancer.
Liso-Cel/Ibrutinib Combo Improves Efficacy in Relapsed/Refractory CLL
Concurrent treatment with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia who were receiving lisocabtagene maraleucel led to measurable effects in both CAR+ and endogenous T cells, both of which were linked with improved efficacy.
Prospective Biomarkers of Pembrolizumab Combo Response Show Feasibility in Frontline Advanced NSCLC
T-cell inflamed gene expression profile and tumor mutational burden assessment was found to be a feasible approach to study the clinical activity of 3 pembrolizumab-based combination regimens in treatment-naïve patients with advanced non–small cell lung cancer.
Tidutamab Shows Early Tolerability, Active Immune Profile in Advanced Neuroendocrine Tumors
Tidutamab was found to be well tolerated with a best overall response of stable disease in patients with advanced, well-differentiated neuroendocrine tumors of pancreatic, gastrointestinal, lung and undetermined origin.
Lenvatinib Plus Pembrolizumab Displays Strong Efficacy in Advanced Endometrial Cancer
The combination of lenvatinib plus pembrolizumab induced durable responses with a manageable safety profile in adults with previously treated, advanced endometrial cancer, according to a long-term follow-up analysis of a phase 1b/2 study (NCT02501096).
ICT01 With or Without Pembrolizumab Shows Early Safety, Activity in Advanced Solid Tumors
ICT01, a humanized anti-BTN3A monoclonal antibody that selectively activates γ9δ2 T cells, has demonstrated early signs of biological activity when given as a single agent or in combination with pembrolizumab in patients with advanced solid tumors.
Pembrolizumab/Chemo Not Effective in Extrapulmonary Poorly Differentiated Neuroendocrine Carcinomas
November 15th 2021The combination of pembrolizumab (Keytruda) and irinotecan- or paclitaxel-based chemotherapy was not found to be effective in pretreated, biomarker-unselected patients with extrapulmonary poorly differentiated neuroendocrine carcinomas.
Surufatinib/Toripalimab Combo Elicits Encouraging Efficacy in Advanced Neuroendocrine Carcinoma
November 13th 2021The combination of surufatinib and toripalimab demonstrated promising clinical activity with a manageable safety profile when used as second-line treatment for patients with advanced neuroendocrine carcinoma.
Eftilagimod Alpha/Paclitaxel Combo Shows Improved OS in Metastatic HR+ Breast Cancer Subsets
The combination of eftilagimod alpha and paclitaxel produced a modest increase in median overall survival in patients with endocrine-resistant hormone receptor–positive/HER2-negative metastatic breast cancer. Though, the effects were significant in patients younger than 65 years old, had low monocytes, or had more aggressive disease.
PD-L1/4-1BB–Directed Bispecific Antibody ATG-101 Shows Preclinical Efficacy Without Hepatotoxicity
November 12th 2021ATG-101, a novel PD-L1/4-1BB bispecific antibody, demonstrated good in vivo efficacy, safety without hepatotoxicity, and pharmacokinetic/pharmacodynamic properties in cynomolgus monkeys.
DuoBody®-CD3x5T4 Induces Efficient T-cell Activation, Tumor Cell Killing in HNSCC Cell Lines
November 12th 2021The DuoBody®-CD3x5T4 was found to induce secretion of granzyme B and efficiently kill tumor cells in co-cultures of healthy donor T cells and patient-derived head and neck squamous cell carcinoma cell lines.
Surufatinib Induces Robust Responses in US Patients with Extrapancreatic and Pancreatic NETs
Surufatinib demonstrated strong antitumor activity along with a manageable safety profile in heavily treated US patients with progressive extrapancreatic neuroendocrine tumors or pancreatic NETs, according to interim phase 1 data.
Overcoming Mechanisms of Resistance Remains at the Forefront for EGFR-Mutant NSCLC
November 8th 2021Although next-generation TKIs have helped to overcome resistance in EGFR-mutated non–small cell lung cancer, a more complete understanding of resistance mechanisms may lead to the ability to overcome resistance to the next generation of these drugs.
Targeted Therapies Make Major Strides in mCRC Management
November 7th 2021The treatment algorithm in metastatic colorectal cancer has gone from accounting only for the sidedness of the primary tumor, performance status, volume of disease, and potential resectability to also include the genetics of the tumor, particularly for patients in need of second-line therapy.
